Sign In / Join

close

Clinical Trials

Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

November 19, 2024

Learn how golcadomide in combination with R-CHOP helped DLBCL patients in a phase 1 clinical trial.

New Clinical Trial with Armored CAR T-cells

October 01, 2024

Understanding CAR T-Cell Therapy and the Armored CAR T-Cell Trial

What are Clinical Trials, and How May They Help Me?

September 30, 2024

Learn about clinical trials to open the door to accessing innovative cancer treatments.

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

May 20, 2024

Columvi (Glofitamab) To Treat Relapsed Or Refractory DLBCL, new treatment option for DLBCL, Clinical Trial for DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

April 25, 2024

New study shows Brentuximab Vedotin combined therapy effective for relapsed DLBCL (lymphoma). Learn about ADCETRIS and its side effects.

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

October 16, 2023

Dr. Gunjan L. Shah and her team at MSK in NY are conducting a clinical trial to reverse T-cell exhaustion by pairing antioxidants alongside CAR T-cell therapy.

The FDA Approves Columvi For Relapsed/Refractory DLBCL

October 08, 2023

The Food and Drug Administration (FDA) approved Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Clinical Trials

Recent Articles

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

New Clinical Trial with Armored CAR T-cells

What are Clinical Trials, and How May They Help Me?

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

The FDA Approves Columvi For Relapsed/Refractory DLBCL

Trending Articles

What Research is Being Discussed for DLBCL at ASH 2024?

How Can Large B-Cell Lymphoma Affect the Lungs?

Azer-cel, a New CAR T-Cell Therapy for DLBCL

ViPOR Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Clinical Trials

Recent Articles

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

New Clinical Trial with Armored CAR T-cells

What are Clinical Trials, and How May They Help Me?

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

The FDA Approves Columvi For Relapsed/Refractory DLBCL

Trending Articles

What Research is Being Discussed for DLBCL at ASH 2024?

How Can Large B-Cell Lymphoma Affect the Lungs?

Azer-cel, a New CAR T-Cell Therapy for DLBCL

ViPOR Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

Get the latest thought leadership on your Diffuse Large B Cell Lymphoma delivered straight to your inbox

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info